Position in RGC
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$802,799
New position
Shares Held
31,569
first reported quarter
Ownership
0.006%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $11,914,926 across 21 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INDV |
Indivior Pharmaceuticals, Inc.
|
55,201 | $2,264,897 | |
| 2 | ZTS |
Zoetis Inc.
|
18,470 | $1,327,254 | |
| 3 | IRWD |
Ironwood Pharmaceuticals Inc
|
259,512 | $1,092,545 | |
| 4 | BCRX |
Biocryst Pharmaceuticals Inc
|
90,210 | $902,100 | |
| 5 | LQDA |
Liquidia Corp
|
10,098 | $805,113 | |
| 6 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
11,219 | $717,455 | |
| 7 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
39,241 | $704,768 | |
| 8 | XERS |
Xeris Biopharma Holdings, Inc.
|
82,830 | $656,013 |
All Filings in RGC
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $802,799 | 31,569 | Shares | Sole | 2026-05-08 | |
| No filing history on record for this holder in this stock. | ||||||